This Article Abstract Full Text (PDF) All Versions of this Article: 105/18/2212    most recent 01.CIR.0000015854.60710.10v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajagopalan, S. Articles by Patel, P. Search for Related Content PubMed PubMed Citation Articles by Rajagopalan, S. Articles by Patel, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB SPIRONOLACTONE Related Collections Pathophysiology Oxidant stress Endothelium/vascular type/nitric oxide

(Circulation. 2002;105:2212.)
© 2002 American Heart Association, Inc.

Basic Science Reports

Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis

Sanjay Rajagopalan, MD; Damon Duquaine, BS; Steven King, PhD; Bertram Pitt, MD; Paresh Patel, MD

From the Departments of Internal Medicine (S.R., D.D., S.K., B.P.) and Psychiatry (P.P.), University of Michigan, Ann Arbor, Mich.

Correspondence to Sanjay Rajagopalan, MD, Section of Vascular Medicine, Division of Cardiology, L3119 Women’s Hospital, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0273. E-mail srajagop@ umich.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Aldosterone has been implicated in the effects of angiotensin II in the vasculature. We hypothesized that there is local expression of the mineralocorticoid receptor (MR) in the vasculature and that the use of a selective aldosterone receptor antagonist (SARA) improves endothelial function in early atherosclerosis.

Methods and Results— New Zealand rabbits were placed on normal chow or 1% cholesterol diets, randomized to placebo or SARA (eplerenone, 50 mg/kg twice daily), and killed at the end of 6 weeks for various studies. In the hyperlipidemic (HL) chow group, there was a 2.3-fold increase in superoxide (O₂^·-) generation. SARA normalized O₂^{· -} generation in intact aortas and reduced NADH and NADPH oxidase activity to basal levels (0.31±0.04 and 0.27±0.02 in HL versus 0.16±0.05 and 0.07±0.02 in HL-SARA, respectively; P<0.01 by ANOVA). This was associated with improvements in peak relaxations to the endothelial-dependent agonist acetylcholine (82±6% in HL-SARA versus 61±4 in HL; P<0.01 by ANOVA; ED₅₀ 6.8x10^-8 mol/L in HL-SARA and 1.2x10^-7 mol/L in HL; P=NS) to near-normal levels. Vessels from the HL group demonstrated hyperreactivity to angiotensin II that could not be corrected with SARA. Plasma aldosterone levels by radioimmunoassay demonstrated a 4- to 5-fold increase in response to SARA but no differences with lipid feeding. Real-time reverse transcriptase–polymerase chain reaction studies revealed expression of MR in the aorta of HL rabbits and those of controls.

Conclusions— MR antagonism improves endothelial function and reduces O₂^·- generation in diet-induced atherosclerosis. Targeting aldosterone by blocking its receptor has potential antiatherosclerotic effects.

Key Words: atherosclerosis • nitric oxide • superoxide • endothelium

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The renin-angiotensin system (RAS) is upregulated in the vasculature of atherosclerotic vessels.¹ It has been hypothesized that locally generated angiotensin II by modulation of NADH/NADPH-dependent oxidases may result in inactivation of nitric oxide (^·NO), setting the stage for progression of atherosclerosis. Indeed, blockade of RAS using an angiotensin II type 1 receptor blocker has been shown to ameliorate endothelium-dependent vasomotion by decreasing the activity of NADH oxidases in the vessel wall and to reduce experimental atherosclerosis.² Recently, there have been several lines of data to suggest that some of the effects of angiotensin II may be mediated by aldosterone. Furthermore, mineralocorticoid receptor (MR) antagonism in patients with an upregulated RAS is associated with improvements in forearm blood flow, suggesting an effect on the nitric oxide synthase (NOS) pathway.³ We therefore sought to determine if pharmacological manipulation of the aldosterone pathway using a selective aldosterone receptor antagonist (SARA) improved ^·NO availability and endothelial function in experimental atherosclerosis.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animal Model
Thirty-two male New Zealand white rabbits (Kuiper Animal Farms, Ind) were used in the study. Sixteen rabbits were fed a standard diet of rabbit chow, and 16 were fed an atherogenic diet consisting of standard rabbit chow supplemented with 1.0% cholesterol (Purina chow). After allowing the rabbits to acclimatize to the chow and environment for 2 weeks, the rabbits were gavage fed with a selective mineralocorticoid receptor antagonist (eplerenone; n=16, 100 mg/kg) or normal saline (n=16) 2 times daily for 6 weeks, after which they were euthanized.

The University of Michigan Committee on Use and Care of Animals approved the protocol. Rabbits were cared for according to standards in the Guide for the Care and Use of Laboratory Animals.

Organ Chamber Studies
Segments of the thoracic aorta were suspended in individual organ chambers filled with Krebs buffer (25 mL) of the following composition (in mmol/L): NaCl 118.3, KCl 4.69, CaCl₂ 1.87, MgSO₄ 1.20, K₂HPO₄ 1.03, NaHCO₃ 25, and glucose 11.1 (pH 7.40), as previously described.⁴ The solution was aerated continuously with a 95% O₂ and 5% CO₂ mixture and maintained at 37°C. Care was taken not to injure the endothelium during preparation of the rings. Tension was recorded with a linear-force transducer. Over a period of 1 hour, the resting tension gradually was increased and the ring segment frequently exposed to 80 mmol/L KCl until the optimal tension for generating force during isometric contraction was reached. In preliminary experiments, this proved to be 3 g in all subsets of animals. The vessels were left at this resting tension throughout the remainder of the study. To prevent synthesis of prostaglandins, all experiments were performed in the presence of 10 µmol/L indomethacin. The vessels were then precontracted with gradual doses of L-phenylephrine (0.15 µmol/L).

Vasodilator Responses
After a stable contraction plateau was reached with phenylephrine, which was 40% to 50% of peak tension generated with maximal-dose KCl, the rings were exposed to the endothelium-dependent agonist acetylcholine (1 nmol/L to 10 µmol/L) or the endothelium-independent agent nitroglycerin (1 nmol/L to 10 µmol/L). The vessels were then washed thoroughly and allowed to equilibrate for another hour before being subjected to vasoconstrictors.

Vasoconstrictor Responses
Vessels were allowed to equilibrate for at least 2 hours at the resting tension of 3 g before being subjected to graded doses of phenylephrine (1 nmol/L to 10 µmol/L) or angiotensin II (1 nmol/L to 0.1 µmol/L). Responses were then expressed as a percentage of the peak response to 80 mmol/L KCl.

Estimation of Aortic O₂^{· -} Production in Intact Segments and NADH/NADPH Oxidase Activity in Vessel Homogenates
O₂^·- anion production was measured in aortic segments using lucigenin (5 µmol/L) chemiluminescence as described previously.⁴ A 10% vessel homogenate was prepared in 50 mmol/L phosphate buffer by homogenizing aortic segments in a glass-to-glass motorized homogenizer. The chemiluminescence that occurred over the ensuing 5 minutes in response to the addition of either NADH or NADPH (both 100 µ mol/L) to 20 µL homogenate was recorded as previously described.⁴ In some experiments, homogenates were incubated with diphenylene iodinium (DPI) (10 µmol/L), and the effect on O₂^·- was evaluated. Values were standardized to the amount of protein present. Protein content was measured using a commercially available kit (D_C protein assay, BioRad Laboratories).

In Situ Detection of O₂^{· -}
Unfixed frozen ring segments were cut into 30-µm sections and placed on a glass slide. The oxidatively active fluorescent dye hydroethidium (2x10^-6 mol/L) was applied to the surface of each section and incubated for a period of 30 minutes at room temperature in a dark humidified chamber. The sections were then scanned with a laser confocal microscope using excitation, and emission wavelengths were 488 and 610 nm, respectively, as described.^5,6 Atherosclerotic and control tissues were processed and imaged in parallel. Laser settings were identical for acquisition of images from atherosclerotic and control specimens.

Quantitative Real-Time Reverse Transcriptase–Polymerase Chain Reaction for MR
MR primers were arrived at from a consensus sequence of human, rat, mouse, and squirrel monkey MRs. Primers were 5' GGGATGGAGACCAAAGGCTACC-3 (starts at translation start codon) and 5'-GTACCTTTGCCCACTTCACGA-3' (in steroid-binding domain). Polymerase chain reaction (PCR) amplification was performed for 35 cycles (95°C for 30 seconds, 55°C for 30 seconds, and 68°C for 3 minutes). DNA was removed from preparations of total RNA using DNase I and DNase removal reagents (Ambion). First-strand cDNA synthesis was performed with random primers and 5 µL of RNA using SuperScript II reverse transcriptase (RT) (Life Technologies). After treatment with RNaseH, samples were diluted into 50 µg/mL herring DNA and used as templates for PCR. PCR amplifications and analyses were performed by TaqMan using an ABI 7700 sequence detection system (Perkin Elmer). The following primers and fluorescent-tagged probes were used to quantify MR: forward primer 5' -CTGTGCCAGGCTTTGATGGT-3', reverse primer 5' -CTCCCATCATCCGGTTCTTG-3', and probe 6FAM-CTGTGAAGGCAGCGGATTCCCCA-TAMRA. The following primers and fluorescent-tagged probes were used to quantify GADPH: 5'-GATGGTGAAGGTCGGAGTGAA-3', reverse primer 5' -AGTTAAAAGCAGCCCTGGTGAC-3', and probe 6FAM- CAGGCGCCCAATGCGGCCA-TAMRA.

Standard curves were generated using dilutions of plasmid DNA containing the target sequence into 50 µg/mL herring DNA. Calculations were based on the linear response of the threshold cycle when PCR products were first detected versus the log of the input template copy number. This response was linear over a wide range of copy numbers (10⁶ to 10¹) achieving correlation coefficients of >0.98.

Statistics
All of the data in the present study are expressed as mean± SEM. Comparisons among groups were made by one-way ANOVA. For differences between paired observations, a t test was used when appropriate. When significance was detected, a post hoc Newman-Keuls multiple-comparison test was performed. All statistical analysis was performed using Graph Pad software (version 3.02).

	Results

Top Abstract Introduction Methods Results Discussion References

 
At the end of 8 weeks of 1% cholesterol administration, average total cholesterol levels in the animals randomized to saline and the SARA group were 1465±333 and 1471±50 mg/dL, respectively (P=NS by paired t test). Total cholesterol levels in the normal chow (NC) and NC-SARA groups were 38±9 and 52±17 mg/dL, respectively. Figure 1 demonstrates plasma aldosterone levels in the experimental groups. Aldosterone receptor antagonism increased circulating levels of aldosterone by 4-fold in the control group (NC-SARA, 1499±243 pg/mL) compared with the saline group (NC, 360±13 pg/mL). Levels increased 5-fold in the hyperlipidemic (HL) group (HL-SARA, 1235±140 pg/mL) compared with the saline group (HL, 230±36 pg/mL). The differences between HL-SARA and NC-SARA were not significant (P=NS by ANOVA).

View larger version (13K): [in this window] [in a new window]   Figure 1. Plasma aldosterone levels in the animal groups. Values are mean±SEM. ***P< 0.001 vs NC and HL, P=NS for HL-SARA vs NC-SARA by ANOVA.

O₂^·- Generation and NADH/NADPH Oxidase Activity
Figure 2 reveals a 2.3-fold increase in O₂^{· -} production in intact aortic segments at the end of 8 weeks of lipid feeding in HL animals compared with controls (3445±863 counts/mg per minute in HL versus 1295±341 counts/mg per minute in NC animals, P<0.01 by ANOVA). In contrast, SARA resulted in normalization of these counts to baseline levels (HL-SARA, 1071±442 counts/mg). Figure 3 depicts oxidase activity in response to NADH and NADPH in the various animal groups. SARA treatment over 6 weeks normalized both NADH-dependent (0.31±0.04 to 0.16±0.05 nmol/mg per protein/min in HL and HL-SARA animals, respectively) and NADPH-dependent oxidases (0.27±0.02 to 0.07±0.02 nmol/mg per protein/min in HL and HL-SARA animals, respectively). In additional experiments, we determined the role of various sources of O₂^·- in homogenates. Homogenates alone and in response to xanthine (100 µmol/L) did not produce any signal beyond background, ruling out contributions by xanthine oxidases. O₂^·- in response to NADH and NADPH was inhibitable by >90% with DPI but not by L-NMMA (10 µmol/L), suggesting a flavin containing oxidoreductase other than NOS (data not shown). We then evaluated in situ production of O₂^·- using H&E staining (hydroethidium) to provide an idea of the spatial distribution of O₂^·- in the vessel wall (Figure 4). Sections of aorta derived from HL animals (n=3) demonstrated intense staining in the intima, media, and adventitia (Figure 4C). In contrast, animals that were rendered HL but received SARA (n=3) had markedly reduced levels of staining in the media and adventitia (Figure 4D). Rabbits fed NC and rabbits fed SARA with NC did not demonstrate changes in spatial localization of O₂^·- signal.

View larger version (13K): [in this window] [in a new window]   Figure 2. The effect of SARA on O2· - production. **P<0.01 vs HL-SARA and NC groups.

View larger version (16K): [in this window] [in a new window]   Figure 3. NADH and NADPH oxidase activity in aortic homogenates. All values are mean±SEM and represent 6 to 8 animals in each group. **P<0.01 vs HL-SARA and NC groups. ** *P<0.001 vs HL-SARA and NC groups.

View larger version (35K): [in this window] [in a new window]   Figure 4. Confocal microscopy images demonstrating dihydro-ethidium (DHE) staining in aorta of rabbits. A and B, Sections from control animals (NC and NC-SARA, respectively). C and D, Sections from HL and HL-SARA animals, respectively. A total of n=3 rabbits in each group were examined, and the representative segment from each group is shown. I indicates intima; M, media; and A, adventitia.

Vasomotor Function With SARA
SARA administration for 6 weeks improved responses to acetylcholine in the HL-SARA group (Figure 5). Peak relaxations markedly improved in the HL-SARA group compared with the HL group (87±3% versus 59±2%, P<0.01 by ANOVA), whereas there was no significant change in the ED₅₀ dose (Table 1). Relaxations to the endothelium-independent agonist nitroglycerin were unaffected by both lipid feeding and treatment with the drug (Figure 5 and Table 1). Vasoconstrictor responses to phenylephrine remained unchanged (peak responses or EC₅₀) in response to lipid feeding and SARA administration (Figure 6 and Table 2). Responses to angiotensin II were heightened in the lipid-fed animals (58±3 and 49±3% in HL-SARA and HL, respectively, P<0.05 for peak constriction versus NC and NC-SARA). Interestingly, SARA administration did not alter the heightened sensitivity to angiotensin II in the HL-SARA animals (Figure 6 and Table 2).

View larger version (12K): [in this window] [in a new window]   Figure 5. Dose-response curves to acetylcholine (Ach) (left) and nitroglycerin (right). Values represent responses to graded doses of drug expressed as a percent of preconstricted tension in response to phenylephrine. All values represent mean±SEM. **P<0.01 vs HL; P=NS for HL-SARA vs NC and NC-SARA by ANOVA.

View this table: [in this window] [in a new window]   Table 1. Effects of SARA on Responses to Acetylcholine and Nitroglycerin

View larger version (11K): [in this window] [in a new window]   Figure 6. Concentration-response curves to phenylephrine (left) and angiotensin II (right). All values are mean±SEM. *P<0.05 versus NC groups. **P<0.01 versus NC groups.

View this table: [in this window] [in a new window]   Table 2. Effects of SARA on Vasoconstrictor Responses

Evidence for Vascular Expression of MR
Real-time RT-PCR analysis of aorta for MR transcript revealed expression in control samples (n=4, 147 625±34 940 copies of MR transcript normalized to GAPDH) and from samples from HL animals n=4, 59 878±37 444).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
These results are the first to demonstrate a role for SARA in ameliorating endothelial function and alleviating free radical stress in early atherosclerosis and supports prior studies that blockade of MR may be beneficial.^7,8

Vascular Responses in Atherosclerosis and the Role of the Mineralocorticoid Pathway
Treatment with SARA improved endothelial function and reduced NADH/NADPH oxidase activity, suggesting an important and previously unreported interaction of MR with O₂^·--generating oxidases in the vasculature. A recent study in humans demonstrated that short-term MR blockade in patients with congestive heart failure who were already taking an ACE inhibitor results in marked improvements in forearm resistance vessel function, suggesting that MR blockade improves endothelial function independent of and in addition to ACE inhibition.³ As shown previously, we demonstrated an increase in the sensitivity to angiotensin II with atherosclerosis.² This is believed to be secondary to an increase in angiotensin II type 1 receptor density in the vessel wall.^2,9 Treatment with SARA did not alter this heightened responsiveness, implying that at least in the HL rabbit, MR antagonism does not alter angiotensin II type 1 receptor–dependent contractile responses.

Potential Mechanisms of Improvement in Vascular Function With SARA
There are a number of potential explanations for the observed findings. The first and foremost is that MR antagonism modulates the influence of aldosterone on O₂^·--generating oxidases. Such an effect would be consistent with previous observations that blockade of the MR results in reduced free radical injury in conditions associated with excess aldosterone.⁷ We have provided evidence for the presence of MR transcript in the vasculature consistent with the notion that the vasculature has the potential to respond to aldosterone. The numbers were too small to make definitive statements about differences between animal groups, and, moreover, we have not reported measures of enzyme/receptor activity. Additional studies will be needed to understand the regulation of the local mineralocorticoid axis in atherosclerosis.

There is the possibility that elevation in potassium levels contributed to the beneficial effects noted in this study.^10,11 We think that this is unlikely, because human studies of MR antagonism with eplerenone at comparable doses have not revealed significant increases in serum potassium.¹² It is possible that MR antagonism resulted in an ACE inhibitor–like effect.³ We did not perform responses to angiotensin I in our study; however, the fact that SARA administration did not restore the hyperresponsiveness seen with angiotensin II in HL animals is indirect evidence that this is unlikely to be secondary to an ACE inhibitor–like effect. Finally, it is possible that the effects could represent a free radical– scavenging effect of eplerenone. The structure of eplerenone does not predict such an effect.¹²

In conclusion, MR antagonism ameliorates endothelial function through an NADH/NADPH oxidase–dependent mechanism. These findings provide a novel role for SARA in the treatment of atherosclerosis.

	Acknowledgments

 
This study was made possible through a grant from Monsanto. The authors acknowledge Dr Clinton Webb and Dr Ricardo Rocha for helpful discussions.

	Footnotes

 
Dr Pitt serves as a consultant to Monsanto.

Received December 31, 2001; revision received February 15, 2002; accepted February 15, 2002.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996; 94: 2756–2767.

2. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999; 99: 2027–2033.

3. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000; 101: 594–597.

4. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916–1923.

5. Miller FJ, Gutterman DD, Rios CD, et al. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998; 82: 1298–1305.

6. Carter WO, Narayanan PK, Robinson JP. Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leuk Biol. 1994; 55: 253–258.

7. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998; 31: 451–458.

8. Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999; 33: 232–237.

9. Yang BC, Phillips MI, Mohuczy D, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998; 18: 1433–1439.

10. Sugimoto T, Tobian L, Ganguli MC. High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. Hypertension. 1988; 11: 579–585.

11. Tobian L, Jahner TM, Johnson MA. High K diets markedly reduce atherosclerotic cholesterol ester deposition in aortas of rats with hypercholesterolemia and hypertension. Am J Hypertens. 1990; 3: 133–135.

12. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000; 57: 1408–1411.

This article has been cited by other articles:

				M. M. Shafiq and A. B. Miller Blocking aldosterone in heart failure Therapeutic Advances in Cardiovascular Disease, October 1, 2009; 3(5): 379 - 385. [Abstract] [PDF]

				J. Xiao, M. Shimada, W. Liu, D. Hu, and A. Matsumori Anti-inflammatory effects of eplerenone on viral myocarditis Eur J Heart Fail, April 1, 2009; 11(4): 349 - 353. [Abstract] [Full Text] [PDF]

				J. W. Funder Reconsidering the Roles of the Mineralocorticoid Receptor Hypertension, February 1, 2009; 53(2): 286 - 290. [Full Text] [PDF]

				S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation, December 9, 2008; 118(24): 2506 - 2514. [Abstract] [Full Text] [PDF]

				N. Oyamada, M. Sone, K. Miyashita, K. Park, D. Taura, M. Inuzuka, T. Sonoyama, H. Tsujimoto, Y. Fukunaga, N. Tamura, et al. The Role of Mineralocorticoid Receptor Expression in Brain Remodeling after Cerebral Ischemia Endocrinology, August 1, 2008; 149(8): 3764 - 3777. [Abstract] [Full Text] [PDF]

				J. T. Mathew, H. Patni, A. N. Chaudhary, W. Liang, A. Gupta, P. N. Chander, G. Ding, and P. C. Singhal Aldosterone induces mesangial cell apoptosis both in vivo and in vitro Am J Physiol Renal Physiol, July 1, 2008; 295(1): F73 - F81. [Abstract] [Full Text] [PDF]

				T. Imanishi, H. Ikejima, H. Tsujioka, A. Kuroi, K. Kobayashi, Y. Muragaki, S. Mochizuki, M. Goto, K. Yoshida, and T. Akasaka Addition of Eplerenone to an Angiotensin-Converting Enzyme Inhibitor Effectively Improves Nitric Oxide Bioavailability Hypertension, March 1, 2008; 51(3): 734 - 741. [Abstract] [Full Text] [PDF]

				C. L. Sartorio, D. Fraccarollo, P. Galuppo, M. Leutke, G. Ertl, I. Stefanon, and J. Bauersachs Mineralocorticoid Receptor Blockade Improves Vasomotor Dysfunction and Vascular Oxidative Stress Early After Myocardial Infarction Hypertension, November 1, 2007; 50(5): 919 - 925. [Abstract] [Full Text] [PDF]

				B. Pitt and G. S. Pitt Added Benefit of Mineralocorticoid Receptor Blockade in the Primary Prevention of Sudden Cardiac Death Circulation, June 12, 2007; 115(23): 2976 - 2982. [Full Text] [PDF]

				I. Z. Jaffe, Y. Tintut, B. G. Newfell, L. L. Demer, and M. E. Mendelsohn Mineralocorticoid Receptor Activation Promotes Vascular Cell Calcification Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 799 - 805. [Abstract] [Full Text] [PDF]

				F. Beygui, J.-P. Collet, J.-J. Benoliel, N. Vignolles, R. Dumaine, O. Barthelemy, and G. Montalescot High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction Circulation, December 12, 2006; 114(24): 2604 - 2610. [Abstract] [Full Text] [PDF]

				M. Nagase, S. Yoshida, S. Shibata, T. Nagase, T. Gotoda, K. Ando, and T. Fujita Enhanced Aldosterone Signaling in the Early Nephropathy of Rats with Metabolic Syndrome: Possible Contribution of Fat-Derived Factors J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3438 - 3446. [Abstract] [Full Text] [PDF]

				H. Oberleithner, C. Riethmuller, T. Ludwig, V. Shahin, C. Stock, A. Schwab, M. Hausberg, K. Kusche, and H. Schillers Differential action of steroid hormones on human endothelium. J. Cell Sci., May 1, 2006; 119(Pt 9): 1926 - 1932. [Abstract] [Full Text] [PDF]

				J. Suzuki, M. Iwai, M. Mogi, A. Oshita, T. Yoshii, J. Higaki, and M. Horiuchi Eplerenone With Valsartan Effectively Reduces Atherosclerotic Lesion by Attenuation of Oxidative Stress and Inflammation Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 917 - 921. [Abstract] [Full Text] [PDF]

				N. Kobayashi, K. Yoshida, S. Nakano, T. Ohno, T. Honda, Y. Tsubokou, and H. Matsuoka Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat Hearts Hypertension, April 1, 2006; 47(4): 671 - 679. [Abstract] [Full Text] [PDF]

				N. C Shah, S. Pringle, and A. Struthers Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 20 - 30. [Abstract] [PDF]

				E. L. Schiffrin Effects of Aldosterone on the Vasculature Hypertension, March 1, 2006; 47(3): 312 - 318. [Full Text] [PDF]

				S. Takai, D. Jin, M. Muramatsu, K. Kirimura, H. Sakonjo, and M. Miyazaki Eplerenone Inhibits Atherosclerosis in Nonhuman Primates Hypertension, November 1, 2005; 46(5): 1135 - 1139. [Abstract] [Full Text] [PDF]

				W. B. Strawn Eplerenone Antagonizes Atherosclerosis, But What Is the Agonist? Hypertension, November 1, 2005; 46(5): 1093 - 1094. [Full Text] [PDF]

				S. Keidar, A. Gamliel-Lazarovich, M. Kaplan, E. Pavlotzky, S. Hamoud, T. Hayek, R. Karry, and Z. Abassi Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients Circ. Res., October 28, 2005; 97(9): 946 - 953. [Abstract] [Full Text] [PDF]

				K. Miyata, M. Rahman, T. Shokoji, Y. Nagai, G.-X. Zhang, G.-P. Sun, S. Kimura, T. Yukimura, H. Kiyomoto, M. Kohno, et al. Aldosterone Stimulates Reactive Oxygen Species Production through Activation of NADPH Oxidase in Rat Mesangial Cells J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2906 - 2912. [Abstract] [Full Text] [PDF]

				A D Struthers Pathophysiology of heart failure following myocardial infarction Heart, May 1, 2005; 91(suppl_2): ii14 - ii16. [Abstract] [Full Text] [PDF]

				A. D Struthers Aldosterone blockade in cardiovascular disease Heart, October 1, 2004; 90(10): 1229 - 1234. [Full Text] [PDF]

				B. Pitt A New HOPE for Aldosterone Blockade? Circulation, September 28, 2004; 110(13): 1714 - 1716. [Full Text] [PDF]

				S. Nakamura, M. Yoshimura, M. Nakayama, T. Ito, Y. Mizuno, E. Harada, T. Sakamoto, Y. Saito, K. Nakao, H. Yasue, et al. Possible Association of Heart Failure Status With Synthetic Balance Between Aldosterone and Dehydroepiandrosterone in Human Heart Circulation, September 28, 2004; 110(13): 1787 - 1793. [Abstract] [Full Text] [PDF]

				A. Garnier, J. K. Bendall, S. Fuchs, B. Escoubet, F. Rochais, J. Hoerter, J. Nehme, M.-L. Ambroisine, N. De Angelis, G. Morineau, et al. Cardiac Specific Increase in Aldosterone Production Induces Coronary Dysfunction in Aldosterone Synthase-Transgenic Mice Circulation, September 28, 2004; 110(13): 1819 - 1825. [Abstract] [Full Text] [PDF]

				A. D. Struthers The clinical implications of aldosterone escape in congestive heart failure Eur J Heart Fail, August 1, 2004; 6(5): 539 - 545. [Abstract] [Full Text] [PDF]

				J E Macdonald, N Kennedy, and A D Struthers Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment Heart, July 1, 2004; 90(7): 765 - 770. [Abstract] [Full Text] [PDF]

				M. K. Nishizaka, M. A. Zaman, S. A. Green, K. Y. Renfroe, and D. A. Calhoun Impaired Endothelium-Dependent Flow-Mediated Vasodilation in Hypertensive Subjects With Hyperaldosteronism Circulation, June 15, 2004; 109(23): 2857 - 2861. [Abstract] [Full Text] [PDF]

				S. Keidar, M. Kaplan, E. Pavlotzky, R. Coleman, T. Hayek, S. Hamoud, and M. Aviram Aldosterone Administration to Mice Stimulates Macrophage NADPH Oxidase and Increases Atherosclerosis Development: A Possible Role for Angiotensin-Converting Enzyme and the Receptors for Angiotensin II and Aldosterone Circulation, May 11, 2004; 109(18): 2213 - 2220. [Abstract] [Full Text] [PDF]

				A. Nishiyama, L. Yao, Y. Nagai, K. Miyata, M. Yoshizumi, S. Kagami, S. Kondo, H. Kiyomoto, T. Shokoji, S. Kimura, et al. Possible Contributions of Reactive Oxygen Species and Mitogen-Activated Protein Kinase to Renal Injury in Aldosterone/Salt-Induced Hypertensive Rats Hypertension, April 1, 2004; 43(4): 841 - 848. [Abstract] [Full Text] [PDF]

				A. D Struthers and T. M MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res, March 1, 2004; 61(4): 663 - 670. [Abstract] [Full Text] [PDF]

				D. Fraccarollo, P. Galuppo, S. Hildemann, M. Christ, G. Ertl, and J. Bauersachs Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1666 - 1673. [Abstract] [Full Text] [PDF]

				B. Pitt, N. Reichek, R. Willenbrock, F. Zannad, R. A. Phillips, B. Roniker, J. Kleiman, S. Krause, D. Burns, and G. H. Williams Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy: The 4E-Left Ventricular Hypertrophy Study Circulation, October 14, 2003; 108(15): 1831 - 1838. [Abstract] [Full Text] [PDF]

				B. Pitt, C. T Stier Jr, and S. Rajagopalan Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 164 - 168. [Abstract] [PDF]

				P. C. White Aldosterone: Direct Effects on and Production by the Heart J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2376 - 2383. [Full Text] [PDF]

				A. Schafer, D. Fraccarollo, S. K Hildemann, P. Tas, G. Ertl, and J. Bauersachs Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction Cardiovasc Res, June 1, 2003; 58(3): 655 - 662. [Abstract] [Full Text] [PDF]

				B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin, et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction N. Engl. J. Med., April 3, 2003; 348(14): 1309 - 1321. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 105/18/2212    most recent 01.CIR.0000015854.60710.10v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajagopalan, S. Articles by Patel, P. Search for Related Content PubMed PubMed Citation Articles by Rajagopalan, S. Articles by Patel, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB SPIRONOLACTONE Related Collections Pathophysiology Oxidant stress Endothelium/vascular type/nitric oxide